Triflusal vs aspirin for prevention of cerebral infarction

Culebras, Antonio; Rotta-Escalante, R; Vila, José F.; Domínguez, Rosa; Abiusi, G.; Famulari, A.; Rey, R.; Bauso-Tosselli, L.; Gori, H; Ferrari, Julia; Reich, Elmar

doi:10.1212/01.wnl.0000113757.34662.aa

Cited by 72 publications

(45 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[560][561][562] A recent noninferiority trial failed to show that sarpogrelate was not inferior to aspirin. 560 Triflusal has been examined in several trials and has not been found to be superior to asprin.…”

Section: Newer Agentsmentioning

confidence: 99%

“…560 Triflusal has been examined in several trials and has not been found to be superior to asprin. 562 Cilostazol has FDA approval for treatment of intermittent claudication and is further along in its development as a stroke treatment. The effectiveness of cilostazol compared with aspirin (doses not specified) was examined initially in a randomized, double-blind pilot study that enrolled 720 patients with a recent ischemic stroke.…”

Section: Newer Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Kernan¹,

Ovbiagele²,

Black³

et al. 2014

Stroke

3,946

1,326

View full text Add to dashboard Cite

The aim of this updated guideline is to provide comprehensive and timely evidence-based recommendations on the prevention of future stroke among survivors of ischemic stroke or transient ischemic attack. The guideline is addressed to all clinicians who manage secondary prevention for these patients. Evidence-based recommendations are provided for control of risk factors, intervention for vascular obstruction, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke. Recommendations are also provided for the prevention of recurrent stroke in a variety of specific circumstances, including aortic arch atherosclerosis, arterial dissection, patent foramen ovale, hyperhomocysteinemia, hypercoagulable states, antiphospholipid antibody syndrome, sickle cell disease, cerebral venous sinus thrombosis, and pregnancy. Special sections address use of antithrombotic and anticoagulation therapy after an intracranial hemorrhage and implementation of guidelines.

show abstract

Section: Newer Agentsmentioning

confidence: 99%

Section: Newer Agentsmentioning

confidence: 99%

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Kernan¹,

Ovbiagele²,

Black³

et al. 2014

Stroke

3,946

1,326

View full text Add to dashboard Cite

show abstract

“…This was a relatively small dose compared to a conventional dose for patients with cerebrovascular disease. 15,19) Thus, adding a small dose of triflusal increased the antiplatelet effect of aspirin in patients with coronary artery disease and this could be used effectively in patients who underwent high risk coronary interventions. Additional action mechanisms of triflusal beyond aspirin: Triflusal was also reported to increase nitric oxide production by neutrophil and endothelial nitric oxide synthase (eNOS) protein expression in neutrophils.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Triple Antiplatelet Therapy Including Triflusal and Conventional Dual Therapy in Patients Who Underwent Drug-Eluting Stent Implantation

et al. 2009

View full text Add to dashboard Cite

SummaryTriflusal is a derivative of acetylsalicylic acid but it exhibits different pharmacological and pharmacokinetic properties. The object of this study was to evaluate the efficacy of additional use of triflusal in patients who underwent drug-eluting stent implantation.First, we prospectively tested platelet function with a rapid platelet function analyzer (VerifyNow Ⓡ -Aspirin) in patients with stable angina (male, age, 61.6 ± 8.3, body weight, 69.3 ± 11.2 kg) who maintained dual (aspirin 100 mg and clopidogrel 75 mg per day, n = 23) or triple (aspirin 100 mg, clopidogrel 75 mg, and triflusal 300 mg per day, n = 23) therapy for more than one month. They were randomly assigned to a group. The triple group showed superior inhibition of arachidonic acid induced platelet aggregation compared to the dual group (420.2 ± 47.7 ARU versus 465.0 ± 71.2 ARU, P = 0.016). Second, we compared composite outcomes (death, myocardial infarction, and nonhemorrhagic stroke) after drug-eluting stent (DES) implantation between the dual (n = 1474) and triple (n = 433) groups in the prospective Seoul National University Hospital drug-eluting stent (SNUH-DES) cohort. The triple group had more current smokers, male patients, and patients with a previous history of revascularization. Also, the triple group underwent more complex interventions such as left main, chronic total occlusion, long lesion, and restenotic lesion than the dual group. In spite of their higher risk profiles, the triple group patients showed comparable composite outcomes (19 cases, 4.4%) to those of the dual group ones (41 cases, 2.8%) (P = 0.12). The triflusal-based triple antiplatelet therapy achieved superior platelet inhibition compared to the dual therapy ex vivo and it could be applied after complex intervention with DES. (Int Heart J 2009; 50: 701-709)

show abstract

“…40 ), a multicentric pilot study, including 431 patients, and Triflusal Aspirin Cerebral Infarction Prevention (TACIP) (ref. 41 ), including 2113 patients.…”

Section: Triflusalmentioning

confidence: 99%

“…In a post hoc analysis, the overall incidence of major and minor hemorrhagic events was significantly lower in TRIF group (2.8%) than the ASA group (8.3%) (ref. 40 ). TRIF is being used in the above mentioned countries, especially in Spain, as an alternative to ASA in cases of ASA intolerance.…”

Section: Triflusalmentioning

confidence: 99%